[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil). Of these 46 patients, 23 treated by CMxMF regimen gave a response rate of 87% (20/23) and 23 treated by CAMF regimen gave a response rate of 82.6% (19/23) (P > 0.05). Following up to the end of June, 1992, 21 patients in CMxMF regimen were still alive with a median survival of 16 (6-24) months and 20 patients in CAMF regimen with a median survival of 12 (3-24) months. The side effects were tolerable in both groups. The authors consider that mitoxantrone is as effective as adriamycin in the treatment of advanced breast cancer.
Chen
J A
JA
First People's Hospital, Xiang-tan municipality, Hunan Province.
D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002277:Carcinoma / Q000188:drug therapy; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage
D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D005472:Fluorouracil; D008727:Methotrexate